Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy
Abstract
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder marked by left ventricular hypertrophy and hypercontractility. This excessive mechanical workload creates an energetic mismatch in which consumption exceeds production, leading to myocardial energy depletion. Although CK (creatine kinase) plays a key role in cardiac energy homeostasis, its involvement in HCM remains unclear. This study investigates how hypercontractility-driven mitochondrial stress and the resulting increase in mitochondrial H 2 O 2 disrupt CK function in HCM. METHODS: CK function was analyzed using myocardial left ventricular tissue from 92 patients with HCM (with and without pathogenic sarcomere variants) and 30 non-failing human controls. Myofilament and mitochondrial CK isoforms were measured using mRNA analysis, protein immunoblotting, enzyme activity assays, mass spectrometry, and redox-sensitive proteomics. To explore links between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction, we used isolated cardiomyocytes from wild-type, mitochondrial-targeted catalase-overexpressing, CK knockout (myofilament and mitochondrial CK deletion), HCM-associated Mybpc3 knock-in, and mito-roGFP2-Orp1 mouse models. We also tested the effects of the Ca 2+ sensitizer EMD-57033, the CK inhibitor 1-fluoro-2,4-dinitrobenzene (DNFB), and the myosin inhibitor MYK-581, a mavacamten derivative. RESULTS: Our analysis revealed significant reductions in myofilament and mitochondrial CK protein levels, as well as CK activity, in myocardium of patients with HCM, primarily because of oxidative modifications of CK. In isolated mouse cardiomyocytes from wild-type and CK knockouts, hypercontractility induced by EMD-57033 elevated mitochondrial H 2 O 2 , causing cellular arrhythmias and CK inactivation. Hypercontractility-induced oxidative stress, arrhythmias, and CK dysfunction were also observed in Mybpc3 knock-in cardiomyocytes. Mitochondrial-targeted catalase-overexpressing mice with enhanced H 2 O 2 scavenging were protected against H 2 O 2 -induced (EMD-57033-mediated) arrhythmias and CK dysfunction. MYK-581 treatment in Mybpc3 knock-in cardiomyocytes reduced hypercontractility, lowered H 2 O 2 production and arrhythmias, and preserved CK function. CK inhibition using DNFB in wild-type cardiomyocytes elevated mitochondrial H 2 O 2 levels and triggered cellular arrhythmias. This mitochondrial oxidation was independently confirmed in mito-roGFP2-Orp1 cardiomyocytes exposed to DNFB. Mitochondrial-targeted catalase-overexpressing mice were protected from DNFB–induced oxidative stress and arrhythmogenic events. CONCLUSIONS: This study reveals a mechanistic link between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction in HCM, perpetuating a cycle of energetic dysfunction. Targeting hypercontractility and oxidative stress through myosin inhibition offers a strategy to restore energy balance and reduce arrhythmic risk in HCM.
Article Details
Authors (30)
Anton Xu
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
David Weissman
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Katharina J. Ermer
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Edoardo Bertero
Department of Internal Medicine, University of Genova, Genova, Italy (E.B.).
Jan M. Federspiel
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Felix Stadler
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Elisa Grünler
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Melina Tangos
Division of Cardiology, Molecular and Experimental Cardiology and Institute of Physiology, Cellular and Translational Physiology, Ruhr University Bochum, Bochum, Germany (M.T., N.H.).
Sevasti Zervou
Radcliffe Department of Medicine, University of Oxford, Oxford, UK (S.Z., C.A.L.).
Mark T. Waddingham
Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita-shi, Osaka, Japan (M.T.W., J.T.P.).
James T. Pearson
Jan-Christian Reil
Smita Scholtz
Clinic of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany (J.-C.R., S.S.).
Jan Dudek
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Michael Kohlhaas
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Alexander G. Nickel
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Lucie Carrier
Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.C., T.E.).
Thomas Eschenhagen
Michelle Michels
Cris Dos Remedios
Victor Chang Cardiac Research Institute, Sydney, NSW, Australia (C.D.R.).
Sean Lal
Faculty of Medicine and Health, Charles Perkins Centre, University of Sydney, NSW, Australia (S.L.).
Leticia Prates Roma
Institute of Biophysics, CIPMM, School of Medicine (L.P.R.), Saarland University, Homburg (Saar), Germany.
Nazha Hamdani
Diederik W.D. Kuster
Department of Physiology, Amsterdam UMC, Amsterdam, the Netherlands (D.W.D.K., J.v.d.V.).
Inês Falcão-Pires
Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal (I.F.-P.).
Christopher N. Johnson
Craig A. Lygate
Radcliffe Department of Medicine, University of Oxford, Oxford, UK (S.Z., C.A.L.).
Jolanda van der Velden
Department of Physiology, Amsterdam UMC, Amsterdam, the Netherlands (D.W.D.K., J.v.d.V.).
Christoph Maack
Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Vasco Sequeira